© 2026 Sinochem Nanjing Corporation,
All Right Reserved
|
HS Code |
759717 |
| Chemicalname | 4-(2-Bromoethyl)indole |
| Molecularformula | C10H10BrN |
| Molecularweight | 224.10 g/mol |
| Casnumber | 7214-47-1 |
| Appearance | White to off-white solid |
| Meltingpoint | 75-77°C |
| Boilingpoint | No data available |
| Purity | Typically ≥98% |
| Solubility | Soluble in organic solvents such as DMSO and chloroform |
| Storageconditions | Store at 2-8°C, protected from light and moisture |
As an accredited 4-(2-Bromoethyl)Oxidole factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 4-(2-Bromoethyl)Oxidole prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Anyone working in organic synthesis knows that the chemistry landscape always asks for versatility and precision. Over the past decade, specialty building blocks have claimed their spot as crucial nodes in most medicinal and material chemistry roadmaps. I remember years ago, reading about various aromatic bromides and their quirks in couplings and substitutions. What makes 4-(2-Bromoethyl)Oxindole particularly notable lies in its unusual combination of an oxindole core linked with a reactive bromoethyl group. That’s not a common structure in the catalog of heterocycles—it opens some less-traveled roads that medicinal chemists are walking more often as drug discovery looks for new mechanisms.
Some might mistake 4-(2-Bromoethyl)Oxindole for another standard functionalized indole, lumping it in with the endless rows of similar alkyl and aryl halides. The bromoethyl side chain, though, drastically alters its personality. I’ve seen more than a few synthetic schemes grind to a halt over problems with selective alkylation or reactivity in indole-based frameworks. This compound gives chemists a greater handle on direct modification at a pivotal position—the four spot, no less—which tends to be chemically less accessible using more traditional halogenations or Friedel-Crafts routes.
My conversations with colleagues always seem to circle back to bottlenecks: how many times have you heard about an otherwise promising molecule that failed because you couldn’t tweak its core fast enough? In those moments, 4-(2-Bromoethyl)Oxindole can genuinely save the day. Its configuration matches well with cross-coupling protocols, opening up N-alkylation and C-alkylation routes that help generate libraries of analogs on tight timelines. This means teams aren’t forced to go back and redesign the molecule from scratch, losing precious weeks or months in optimization.
For medicinal chemistry projects hunting for next-generation kinase inhibitors or CNS agents, indole-based motifs continue to dominate starting points. When the need arises to append short, reactive tethers onto the core, generic indole alkylations often misfire, overreact, or yield awkward mixtures. Here, the built-in bromoethyl handle offers reliable entry to functionalize without scrambling the rest of the system. That can translate to more streamlined routes, lower costs, and less chemical waste.
Chemists tend to look past brochure descriptions and want the real facts. The product usually appears as an off-white crystalline solid, with batch purity levels typically exceeding 97% based on rigorous HPLC or NMR. Impurities tend to cluster around simple dibromo or hydrolyzed derivatives; in my experience, most reputable sources keep these secondary components well below one percent. This kind of purity is a must when every reaction step hangs on the success of a single transformation—the slightest contamination can tank a whole run.
I’ve watched the specs evolve over time. Earlier, inconsistent handling through storage made these types of aryl halides less reliable—decomposition and darkening were common. Improved packaging, use of inert atmosphere, and attention to trace moisture content now keep 4-(2-Bromoethyl)Oxindole stable for over a year in most labs. Storing it at 2-8°C, away from sunlight, preserves its reactivity more reliably than many related indolic compounds. That extra shelf life takes pressure off project managers and cuts wasted material costs too.
With the explosion of interest in fragment-based drug design, chemists want ways to bolt together small pieces into more complex targets. Many halogenated indoles exist, but attaching an active side chain at the four position opens different options for how fragments are linked, merged, or extended. A nitro or a simple methyl group at the same place doesn’t offer the same flexibility in C–C or C–N couplings that the bromoethyl chain does. I still remember the first time a teammate of mine tried to introduce a chain at this spot via direct C–H activation—it worked, but it was messy, unpredictable, and needed a huge cleanup. Switching to 4-(2-Bromoethyl)Oxindole for the next round, the overall process shrank from weeks to days. The difference that makes in the life of a postdoc or bench chemist can’t be overstated.
If you compare this to more standard bromoindoles or bromoethyl aromatics, you find this oxindole offers two distinct reactive centers that are hard to replicate on other scaffolds. The oxindole ring is a proven bioisostere; medicinal chemists reach for it because it often mimics peptide backbones or nucleobase analogs in binding sites. Overlay that with a bromoalkyl chain, and these molecules serve as strong platforms for click chemistry, Suzuki-Miyaura or Buchwald-Hartwig couplings, and direct nucleophilic substitution. Other products simply don’t offer quite the same level of chemical maneuverability—all those transformation options open doors to structure-activity relationships that might otherwise remain closed.
A main reason 4-(2-Bromoethyl)Oxindole stands out comes from its dual role: it’s not just a functionalized aromatic, and not just a simple halide. It bridges the world of medicinal chemistry and more academic synthetic research. Many building blocks focus too narrowly—either pure practicality for known drugs, or exotic frameworks meant just for complex academic targets. This one strikes a balance. I’ve seen research groups use it to make both blockbuster candidate drugs and mechanism probes for basic science.
Other bromooxidoles, such as those with simple dibromo or methyl substitutions, lack the same ability to connect new bulk at defined points or to serve as short-linker intermediates in cross-coupling chains. You don’t get the same selectivity or the same final compound purity. For process chemists, that means you’re more likely to avoid the trap of low-yield side reactions or time-consuming purifications. Medicinal teams want to see clear SAR data—and to get that, you need a chemistry workflow that offers reproducible, clean conversion every time you run the transformation.
It’s easy to gloss over the everyday victories that compounds like this offer. Early in my career, I remember scrambling to piece together analog libraries from unreliable starting materials. Bottlenecks came from both lack of reactivity and painful purifications. Now, tools like 4-(2-Bromoethyl)Oxindole fill in these gaps. Colleagues from two major pharma companies pointed out they were able to accelerate hit-to-lead timelines by about 30% using this product versus more generic alkyl bromides; they credited cleaner reactions and easier downstream isolation. For academic teams whose funding periods are measured in tight semesters, that sort of acceleration is priceless.
The broader impact of such specialty intermediates grows as the expectations for chemical innovation rise. Since major regulatory agencies started pressing for greater chemical diversity and greener manufacturing, the ability to generate more candidates with less chemical waste turns into a crucial selling point. Few alternatives can match this oxindole’s reactivity profile while avoiding troublesome byproducts notorious in indolic chemistry.
Every synthetic chemist has faced those moments when challenging functionalization stalls an entire workflow. The annual scramble for better starting materials has forced research teams to push their suppliers for both higher purity and consistent physical properties. 4-(2-Bromoethyl)Oxindole offers the distinct advantage that, so long as the lot is clean, it behaves predictably under most standard conditions. This takes some guesswork out of reaction optimization, allowing junior researchers to focus on designing molecules rather than babysitting tricky transformations. The compounded time savings add up, especially as research deadlines get tighter every year.
Some challenges linger. Storage and handling of lightly functionalized aromatic halides remain a sticking point. Labs still struggle with moisture uptake and slow decomposition in open containers. The best results in my experience come from using airtight containers, minimal air exposure, and working quickly at low temperatures. These operational details matter: a bit of inattention can spoil an entire batch and undermine synthetic plans. There’s an opportunity here for vendors to push storage solutions forward—single-use ampules, novel desiccant packaging, or built-in inert atmosphere pouches could extend shelf lives and prevent waste.
Another issue comes from global sourcing. High-quality 4-(2-Bromoethyl)Oxindole remains somewhat niche. Only a handful of established vendors reliably offer material that meets the rigorous specs high-stakes drug discovery programs demand. Access could be broadened if more manufacturers invested in robust process controls and transparent QC reporting. For customers, building relationships with suppliers who provide batch-level documentation and purity data helps avoid the nightmare of discovering a lot-to-lot variation only after hundreds of hours of work.
Many chemists now look beyond just the in-lab direct workhorse characteristics of a product—they want the full environmental story as well. Although specialty halides like 4-(2-Bromoethyl)Oxindole are not produced on a commodity scale, their environmental footprint is non-trivial because byproducts and residual reagents can persist throughout downstream processes. In the past, large volumes of halogenated solvents coupled with inefficient purifications led to excess hazardous waste. These days, the move towards better process efficiency, sealed reaction vessels, and higher substrate reactivity cuts down on both solvent use and exposure risks.
I’ve watched several teams succeed by integrating greener solvents—ethyl acetate, toluene in place of more toxic or persistent options—without losing the key transformations. Modern protocols often make use of microwave irradiation or flow technology, which further reduces unwanted decomposition and limits chemical exposure. The higher initial purchase cost of well-formulated 4-(2-Bromoethyl)Oxindole quickly pays off if it saves even one purification step or reduces toxic waste volume by a factor of two or three over a multi-step campaign.
Waste minimization is only part of the story. Regulatory bodies are watching residual halides, brominated impurities, and potential environmental persistence far more closely. As researchers, sharing detailed use protocols and monitoring residuals down to the ppm range will shape best practices and help ease potential future regulatory burdens. This kind of proactive self-reporting has become the new standard in responsible lab management—no chemistry is “green” today unless it’s easy to track, manage, and dispose of every byproduct.
Research teams moving from milligram-scale discovery to pilot plant synthesis will encounter a different set of hurdles. On the bench, 4-(2-Bromoethyl)Oxindole’s predictable performance and clean reactivity profile can lull you into underestimating problems at larger scale. Structural bromides, even with convenient reactivity, can sometimes promote unwanted side reactions under scale-up conditions—radical formation, over-alkylation, or cross-polymerization if not carefully monitored.
My experience with scale-up teams underlines a couple of practical recommendations. First, always screen a small lot on pilot plant equipment before commiting to kilo or multi-kilo synthesis. Reaction pathways that look trivial at gram scale can agglomerate, char, or create foam when running continuously in reactors. Second, pay extra attention to your quench and workup protocols. The bromoethyl group, once displaced, can generate low-molecular-weight alkyl bromides—these can be tricky to dispose of and are regulated at low workplace exposure limits in many jurisdictions.
Scaling a promising candidate for preclinical or tox studies often means direct collaboration between process chemists and safety engineers. Using clean and well-characterized 4-(2-Bromoethyl)Oxindole as an input makes the documentation and hazard evaluation steps more transparent. It’s easier to secure a site license or satisfy QC auditors when you can show batch-wise consistency, traceability, and tight impurity specs, all supported by independent testing.
The constant search for higher throughput and smarter molecular design in drug discovery only grows more fevered every year. Many industry veterans trace the bottleneck in pipeline progression to slow or unpredictable input materials. In a world where screening hundreds of analogs within weeks is the baseline, specialty reagents like 4-(2-Bromoethyl)Oxindole make a tangible difference. Project managers tracking SAR data for a series of oxindole derivatives can hit their milestone reviews without the typical workflow jams. I’ve seen entire discovery campaigns get back on track simply by swapping in a higher-purity bromoethyl reagent.
This explains the product’s frequent mention in recent medicinal chemistry breakthroughs—whether the goal is novel kinase inhibitors, CNS-active scaffolds, or just a new lead against an old target class. Its reliability translates outwards: downstream ADME studies tend to show cleaner results, toxicologists deal with fewer surprise bioisosterism issues from rogue side products, and patent filings enjoy broader, clearer coverage for chemical space explored.
Many in the field see 4-(2-Bromoethyl)Oxindole not only as another capo in the toolkit, but as an enabler of creative chemistry. Junior researchers, in particular, benefit from materials that behave with minimal fuss: fewer failed experiments, more robust analytical checkpoints, and more time spent learning rather than trouble-shooting. There’s a reason well-designed intermediates help raise the overall quality of a research environment—the less you worry about starting material, the more you can think about bigger-picture scientific questions.
Feedback from working chemists highlights opportunities for incremental improvement. Some users, for example, want more granular data about residual solvents, trace metal content, or reactivity with a wider menu of coupling partners. If suppliers provide more batch-level certification and analytical data, the trust in the product only grows. An online portal for real-world reaction feedback and troubleshooting could help democratize hard-won lab knowledge and avoid duplicate errors across research groups.
The demands placed on specialty building blocks have never been higher. Between regulatory scrutiny, the need for ever more diverse compound libraries, and relentless pressure to speed up the research clock, products like 4-(2-Bromoethyl)Oxindole find themselves in the spotlight. These aren’t just materials; they’re levers for innovation—small differences in reactivity or purity translate directly into million-dollar decisions downstream.
Chemists selecting their next round of precursors, particularly at critical junctions in discovery or manufacturing, now value both hard specs and the stories of successful projects that came before. That means less patience for unreliable inputs, ambiguous documentation, or mysterious supply interruptions. High-purity, well-distributed materials sidestep unnecessary headaches and let teams focus on the scientific goals that matter—better therapeutics, more sustainable syntheses, and a tiny bit of peace of mind when the regulatory auditors arrive.
